López Del Moral Covadonga, Wu Kaiyin, Naik Marcel, Osmanodja Bilgin, Akifova Aylin, Lachmann Nils, Stauch Diana, Hergovits Sabine, Choi Mira, Bachmann Friederike, Halleck Fabian, Schrezenmeier Eva, Schmidt Danilo, Budde Klemens
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Valdecilla Biomedical Research Institute (IDIVAL), Santander, Spain.
Front Med (Lausanne). 2022 Sep 16;9:943502. doi: 10.3389/fmed.2022.943502. eCollection 2022.
donor-specific HLA antibodies (dnDSA) are key factors in the diagnosis of antibody-mediated rejection (ABMR) and related to graft loss.
This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to assess the impact of mean fluorescence intensity (MFI) evolution as detected by annual Luminex screening. All 400 kidney transplant recipients with 731 dnDSA against the last graft (01/03/2000-31/05/2021) were included.
During 8.3 years of follow-up, ABMR occurred in 24.8% and graft loss in 33.3% of the cases, especially in patients with class I and II dnDSA, and those with multiple dnDSA. We observed frequent changes in MFI with 5-year allograft survivals post-dnDSA of 74.0% in patients with MFI reduction ≥ 50%, 62.4% with fluctuating MFI (MFI reduction ≥ 50% and doubling), and 52.7% with doubling MFI (log-rank < 0.001). Interestingly, dnDSA in 168 (24.3%) cases became negative at some point during follow-up, and 38/400 (9.5%) patients became stable negative, which was associated with better graft survival. Multivariable analysis revealed the importance of MFI evolution and rejection, while class and number of dnDSA were not contributors in this model.
In summary, we provide an in-depth analysis of the natural course of dnDSA after kidney transplantation, first evidence for the impact of MFI evolution on graft outcomes, and describe a relevant number of patients with a stable disappearance of dnDSA, related to better allograft survival.
供者特异性 HLA 抗体(dnDSA)是抗体介导的排斥反应(ABMR)诊断的关键因素,且与移植物丢失相关。
本回顾性研究旨在评估 dnDSA 在移植物功能和肾移植存活中的自然病程,并通过每年的 Luminex 筛查评估平均荧光强度(MFI)演变的影响。纳入了所有 400 例针对最后一次移植(2000 年 3 月 1 日至 2021 年 5 月 31 日)产生 731 种 dnDSA 的肾移植受者。
在 8.3 年的随访期间,24.8%的病例发生了 ABMR,33.3%的病例出现了移植物丢失,尤其是在具有 I 类和 II 类 dnDSA 的患者以及具有多种 dnDSA 的患者中。我们观察到 MFI 频繁变化,dnDSA 后 5 年移植物存活率在 MFI 降低≥50%的患者中为 74.0%,MFI 波动(MFI 降低≥50%且翻倍)的患者中为 62.4%,MFI 翻倍的患者中为 52.7%(对数秩检验<0.001)。有趣的是,168 例(24.3%)病例中的 dnDSA 在随访期间的某个时间点变为阴性,38/400(9.5%)患者变为稳定阴性,这与更好的移植物存活相关。多变量分析揭示了 MFI 演变和排斥反应的重要性,而 dnDSA 的类别和数量在该模型中并非影响因素。
总之,我们对肾移植后 dnDSA 的自然病程进行了深入分析,首次证明了 MFI 演变对移植物结局的影响,并描述了相当数量的 dnDSA 稳定消失的患者,这与更好的数据移植存活相关。